vTv Therapeutics (VTVT)
NASDAQ:VTVT
Want to see VTVT full AI Analyst Report?
Top Page
vTv Therapeutics
(NASDAQ:VTVT)
Select Model
Select Model
Rating:48Neutral
Price Target:
$32.00
▼(-16.05% Downside)
Action:ReiteratedDate:03/17/26
The score is primarily held down by weak financial performance (no consistent revenue, sizable losses, and sustained cash burn). Technicals are modestly supportive with the stock above major moving averages, but momentum is not strong. Valuation is constrained by loss-making results and no dividend, while recent corporate events provide a meaningful positive offset through cash runway visibility and partnership-driven funding potential.
Positive Factors
Late-stage pipeline / Breakthrough designation
Cadisegliatin's Phase 3 status and FDA Breakthrough designation target a large, underserved type 1 diabetes market. A successful pivotal program can convert vTv from a pure R&D biotech into a partnerable or commercial-stage company, materially improving long-term financing optionality and strategic alternatives.
Negative Factors
Persistent cash burn
Sustained negative operating cash flow and free cash flow indicate clinical development is consuming capital at scale. This structural burn necessitates recurrent financing or milestone receipts, raising dilution risk and limiting the firm's ability to fund parallel programs or commercialization investments without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage pipeline / Breakthrough designation
Cadisegliatin's Phase 3 status and FDA Breakthrough designation target a large, underserved type 1 diabetes market. A successful pivotal program can convert vTv from a pure R&D biotech into a partnerable or commercial-stage company, materially improving long-term financing optionality and strategic alternatives.
Read all positive factors
vTv Therapeutics (VTVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$136.93M
Dividend YieldN/A
Average Volume (3M)5.07K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth-100.00%
EPS Growth1.93%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding3,938,654
10 Day Avg. Volume5,801
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.60K
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$53.33Price Target Upside39.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.84
Revenue Forecast (FY)$13.33M
vTv Therapeutics Business Overview & Revenue Model
Company Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, vTv Therapeutics has historically not generated meaningful recurring revenue from product sales because it does not have widely disclosed commercial products. Its cash inflows have primarily been asso...
vTv Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 1.02M | 0.00 | 2.02M | 4.00M |
| Gross Profit | -16.00K | 1.02M | 0.00 | 2.02M | 4.00M |
| EBITDA | -32.79M | -22.52M | -25.86M | -24.77M | -17.52M |
| Net Income | -26.97M | -18.46M | -20.25M | -19.16M | -12.99M |
Balance Sheet | |||||
| Total Assets | 89.90M | 38.27M | 11.02M | 33.24M | 25.47M |
| Cash, Cash Equivalents and Short-Term Investments | 88.93M | 36.75M | 9.45M | 12.13M | 13.41M |
| Total Debt | 0.00 | 169.00K | 529.00K | 716.00K | 932.00K |
| Total Liabilities | 25.46M | 23.96M | 29.57M | 27.40M | 10.25M |
| Stockholders Equity | 64.44M | 12.20M | -24.68M | -10.74M | -9.74M |
Cash Flow | |||||
| Free Cash Flow | -25.25M | -25.31M | -19.08M | -15.27M | -19.31M |
| Operating Cash Flow | -25.25M | -25.31M | -19.08M | -15.25M | -19.31M |
| Investing Cash Flow | 0.00 | 0.00 | 4.40M | -21.00K | 0.00 |
| Financing Cash Flow | 77.44M | 52.61M | 12.00M | 13.98M | 26.98M |
vTv Therapeutics Technical Analysis
Positive
38.12
Price Trends
36.52
Positive
35.50
Positive
27.69
Positive
Market Momentum
0.27
Positive
52.03
Neutral
38.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Positive. The current price of 38.12 is above the 20-day moving average (MA) of 38.01, above the 50-day MA of 36.52, and above the 200-day MA of 27.69, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 52.03 is Neutral, neither overbought nor oversold. The STOCH value of 38.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTVT.
vTv Therapeutics Risk Analysis
vTv Therapeutics disclosed 62 risk factors in its most recent earnings report. vTv Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
vTv Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $174.85M | -4.05 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $69.61M | -2.21 | 240.83% | ― | -41.52% | 42.50% | |
49 Neutral | $106.99M | -1.64 | -81.77% | ― | ― | ― | |
49 Neutral | $76.77M | -0.79 | -69.56% | ― | ― | 29.91% | |
48 Neutral | $136.93M | -12.49 | -74.07% | ― | -100.00% | 1.93% | |
48 Neutral | $77.95M | -2.07 | -30.19% | ― | ― | 63.31% |
* Healthcare Sector Average
VTVT
vTv Therapeutics
32.76
9.59
41.40%
ATHE
Alterity Therapeutics
4.41
0.93
26.72%
IFRX
InflaRx
1.48
0.26
21.31%
CLNN
Clene
5.91
2.88
95.05%
PLRX
Pliant Therapeutics
1.24
-0.23
-15.65%
ADAG
Adagene
3.69
2.26
158.04%
vTv Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway
Positive
Mar 11, 2026
On March 10, 2026, vTv Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on diabetes and other metabolic and immune-related diseases, posted an updated corporate slide presentation highlighting its late-stage pipeline and fina...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength
Positive
Feb 26, 2026
On February 26, 2026, vTv Therapeutics posted an updated corporate slide presentation outlining the progress of cadisegliatin, its late-stage oral adjunctive therapy candidate for type 1 diabetes, and its broader pipeline. The company highlighted ...
Business Operations and StrategyPrivate Placements and Financing
vTv Therapeutics Expands Global HPP737 Rights with Newsoara
Positive
Feb 2, 2026
On January 30, 2026, vTv Therapeutics LLC amended its 2018 license agreement with Newsoara Biopharma, restoring and significantly expanding Newsoara’s rights to develop and commercialize the PDE4 inhibitor HPP737 on a worldwide basis, contin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.